1. Home
  2. SUPN vs HNI Comparison

SUPN vs HNI Comparison

Compare SUPN & HNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$48.46

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

HNI

HNI Corporation

HOLD

Current Price

$39.95

Market Cap

2.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPN
HNI
Founded
2005
1944
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Office Equipment/Supplies/Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2010
1994

Fundamental Metrics

Financial Performance
Metric
SUPN
HNI
Price
$48.46
$39.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$61.60
$70.00
AVG Volume (30 Days)
909.5K
827.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
3.73%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$392,755,000.00
$2,839,000,000.00
Revenue This Year
$22.70
$117.19
Revenue Next Year
$19.14
$3.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.37
52 Week Low
$32.21
$28.93
52 Week High
$59.68
$53.29

Technical Indicators

Market Signals
Indicator
SUPN
HNI
Relative Strength Index (RSI) 57.13 65.46
Support Level $47.48 $38.04
Resistance Level $52.36 $47.51
Average True Range (ATR) 1.59 1.64
MACD 0.50 0.11
Stochastic Oscillator 59.27 76.08

Price Performance

Historical Comparison
SUPN
HNI

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

About HNI HNI Corporation

HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.

Share on Social Networks: